Lilly Exploring Strategic Alternatives for Animal Health Biz
Sluggish growth is the main driver for the decision.. Source: BioSpace
Sluggish growth is the main driver for the decision.. Source: BioSpace
The company plans to initiate a Phase 2 clinical trial this year with AVR-RD-01 in Fabry disease. Source: BioSpace
Vertex is keeping its promise of advancing triple combination treatments for patients with cystic fibrosis and investors are happy. Source: BioSpace
Celltrion are down more than 5 percent after the company announced it received a warning letter from the FDA after the regulatory agency inspected a company drug manufacturing facility. Source:…
Here is a look at a few important regulatory events scheduled for the month of February. Source: BioSpace
Dr. Paul has been with the company for six years since its inception, initially as president of R&D, Source: BioSpace
Today STADA announced the appointment of Peter Goldschmidt as new CEO and chairman of the board. Source: BioSpace
Nearly 14 percent of all drugs in clinical trials eventually win approval from the FDA — a much higher percentage than previously thought, according to a new study from the…
The Association for Accessible Medicines’ Biosimilars Council submitted an amicus brief supporting Pfizer in its antitrust lawsuit against Johnson & Johnson, arguing the company’s practices will keep biologics prices high…
Eighteen Democratic senators joined Health, Labor, Education and Pensions Committee Ranking Member Patty Murray (Wash.) in calling on the Government Accountability Office to review the Trump administration’s efforts against the…